Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors No significant financial relationships to ...

First, bbT369 targets a novel combination of antigens highly expressed in B cell lymphomas, CD79a and CD20. CD79a, a novel target, is a critical signaling component of the B cell receptor and CD20 is ...

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin ...

CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an ...

CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...

The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research. CAR T-cell ...